US 11,814,394 B2
Exatecan derivatives, linker-payloads, and conjugates and thereof
Gang Qin, Suzhou (CN); Tony Yantao Zhang, Shanghai (CN); Guangming Chen, Shanghai (CN); Paul H. Song, Suzhou (CN); Boyu Zhong, Shanghai (CN); and Mingyu Hu, Suzhou (CN)
Assigned to GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD., Suzhou (CN)
Filed by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD., Suzhou (CN)
Filed on Nov. 8, 2022, as Appl. No. 18/053,459.
Claims priority of application No. PCT/CN2021/130896 (WO), filed on Nov. 16, 2021.
Prior Publication US 2023/0271977 A1, Aug. 31, 2023
Int. Cl. C07D 491/22 (2006.01)
CPC C07D 491/22 (2013.01) 7 Claims
 
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of formula (i):

OG Complex Work Unit Chemistry
wherein,
a is 0;
the carbon atoms marked with p1* and p2* each is asymmetric center, and the asymmetric center is S configured, R configured or racemic;
L1 is selected from —CH2— and

OG Complex Work Unit Chemistry
R1 is Cl; and
R2 is F.